You searched for "prostate cancer"
Cost effectiveness of prostate cancer screening in Europe
Prostate cancer (PCa) stands as the most prevalent cancer and the third leading cause of cancer-related deaths among men in Europe. According to data from the European Commission, in 2020, PCa represented a staggering 23.2% of all new cancer cases...Rishi Sunak joins Prostate Cancer Research as an ambassador
Rishi Sunak with three prostate cancer patients at the Oxford BioDynamics labs. (From left to right: Dafydd Charles, Briane Milne, Rishi Sunak, Alfred Samuels). Former UK Prime Minister Rishi Sunak has joined Prostate Cancer Research as an ambassador, to champion...MRI screening for prostate cancer: a step towards a ‘prostagram’
The UK National Screening Committee has been calling for further research into alternative screening tests for prostate cancer. The committee decided against prostate cancer screening using prostate specific antigen (PSA) testing on the basis that “PSA is still a poor...Recent advances in the management of castration resistant prostate cancer
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...Movember addresses sexual health needs in prostate cancer patients
When Travis Garone and Luke Slattery met up in the Gypsy Bar in Melbourne for a quiet beer back in 2003 and came up with the idea for Movember, they could not have imagined what it would become and the...
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
Abiraterone acetate, the prodrug of abiraterone, blocks endogenous androgen synthesis by inhibiting cytochrome p-450c17, a critical enzyme in androgen biosynthesis. Its active D4A metabolite also has anti-tumour effects through possibly multiple mechanisms. 3-5% of men diagnosed with prostate cancer in...
PET imaging of prostate-specific membrane antigen in prostate cancer
Molecular imaging utilising prostate-specific membrane antigen (PSMA) as a target has increasingly been mentioned at key conferences and meetings. PSMA is a membrane metalloenzyme that is overexpressed in prostate cancer, with the degree of expression appears to correlate with tumour...
Prostate cancer detection rate of MRI-TRUS fusion vs. systematic biopsy
With the advent of one-stop prostate cancer diagnostic clinics, the findings of this study are of interest to readers who may be considering introducing the technique of magnetic resonance imaging transrectal ultrasound (MRI-TRUS) fusion biopsies to their practice. A retrospective...
Incidence and risk factors of suicide after a prostate cancer diagnosis
This is an observational study looking at 1,281,393 men diagnosed with prostate cancer and 842,294 matched prostate cancer-free men. There was an overall increased relative risk of suicide of 2.01 in men diagnosed with prostate cancer compared to those without,...
Factors and time to conversion from prostate cancer active surveillance to treatment
Active surveillance is the standard of care for men with low-risk and selected men with favourable intermediate risk prostate cancer. The aim is to reduce the morbidity and mortality of overtreatment of non-clinically significant prostate cancer. A significant proportion progress...
